What, if Any, Role Is There for BRAF-Targeted Therapy in -Mutant Melanoma?
作者信息
Sullivan Ryan J
机构信息
Massachusetts General Hospital Cancer Center, Boston, MA.
出版信息
J Clin Oncol. 2022 Dec 20;40(36):4161-4165. doi: 10.1200/JCO.22.01066. Epub 2022 Jul 21.
Abstract
摘要
相似文献
1
What, if Any, Role Is There for BRAF-Targeted Therapy in -Mutant Melanoma?BRAF靶向治疗在BRAF突变型黑色素瘤中（若有）发挥着怎样的作用？
J Clin Oncol. 2022 Dec 20;40(36):4161-4165. doi: 10.1200/JCO.22.01066. Epub 2022 Jul 21.
2
Sequencing of Targeted Treatment and Immunotherapy in Advanced -Mutant Melanoma.晚期BRAF V600E突变型黑色素瘤的靶向治疗与免疫治疗序贯研究
J Clin Oncol. 2023 Apr 20;41(12):2295-2296. doi: 10.1200/JCO.22.02250. Epub 2023 Feb 15.
3
Targeted therapy resistance mechanisms and therapeutic implications in melanoma.黑色素瘤中的靶向治疗耐药机制及其治疗意义
Hematol Oncol Clin North Am. 2014 Jun;28(3):523-36. doi: 10.1016/j.hoc.2014.03.001.
4
Targeted therapies for cutaneous melanoma.皮肤黑色素瘤的靶向治疗
Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3.
5
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.BRAF 突变型黑色素瘤的治疗：维莫非尼及其他疗法的作用。
Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30.
6
Targeted therapy for melanoma: rational combinatorial approaches.黑色素瘤的靶向治疗：合理的联合治疗方法。
Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18.
7
Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?单次BRAF野生型检测足以将黑色素瘤患者排除在维莫非尼治疗之外吗？
J Invest Dermatol. 2014 May;134(5):1468-1470. doi: 10.1038/jid.2013.378. Epub 2013 Sep 11.
8
Therapeutic targets in melanoma: map kinase pathway.黑色素瘤的治疗靶点：丝裂原活化蛋白激酶途径
Curr Oncol Rep. 2006 Sep;8(5):400-5. doi: 10.1007/s11912-006-0065-x.
10
Targeted Therapy in Advanced Melanoma With Rare Mutations.晚期黑色素瘤伴罕见突变的靶向治疗。
J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3.
引用本文的文献
1
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring mutations.免疫检查点抑制剂在携带特定突变的晚期非小细胞肺癌中的疗效
Transl Lung Cancer Res. 2023 Feb 28;12(2):219-229. doi: 10.21037/tlcr-22-613. Epub 2023 Feb 25.
本文引用的文献
1
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.达拉非尼、曲美替尼和 AT13387 联合治疗 BRAF 突变型实体瘤患者的剂量递增试验。
Cancer. 2023 Jun 15;129(12):1904-1918. doi: 10.1002/cncr.34730. Epub 2023 Apr 11.
2
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With V600-Mutant Melanoma.COLUMBUS 5 年更新：依维莫司或恩考芬尼联合比尼替尼对比维莫非尼用于 V600 突变型黑色素瘤患者的随机、开放标签、III 期试验。
J Clin Oncol. 2022 Dec 20;40(36):4178-4188. doi: 10.1200/JCO.21.02659. Epub 2022 Jul 21.
3
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.晚期黑色素瘤患者免疫检查点阻断失败后的 MAPKinase 抑制 - 多中心前瞻性皮肤癌登记处 ADOREG 的评估。
Eur J Cancer. 2022 May;167:32-41. doi: 10.1016/j.ejca.2022.02.023. Epub 2022 Mar 30.
4
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.随机 III 期临床试验评估 Spartalizumab 联合 Dabrafenib 和 Trametinib 治疗 V600 突变不可切除或转移性黑色素瘤。
J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14.
5
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.BAMM（BRAF 自噬和 MEK 抑制在黑色素瘤中的作用）：达拉非尼、曲美替尼和羟氯喹治疗晚期 BRAFV600 突变型黑色素瘤的 I/II 期试验。
Clin Cancer Res. 2022 Mar 15;28(6):1098-1106. doi: 10.1158/1078-0432.CCR-21-3382.
6
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.纳武利尤单抗联合伊匹单抗或纳武利尤单抗对比伊匹单抗治疗晚期黑色素瘤患者的长期结局。
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
7
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.考比替尼联合威罗非尼治疗 BRAFV600 突变阳性晚期黑色素瘤的 5 年结果：coBRIM 研究的扩展随访。
Clin Cancer Res. 2021 Oct 1;27(19):5225-5235. doi: 10.1158/1078-0432.CCR-21-0809.
8
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.辅助帕博利珠单抗对比安慰剂用于切除的 III 期黑色素瘤（EORTC 1325-MG/KEYNOTE-054）：来自一项双盲、随机、对照、III 期试验的无远处转移生存结果。
Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12.
9
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.辅助靶向治疗后黑素瘤的复发模式和管理：一项多中心分析。
Br J Cancer. 2021 Feb;124(3):574-580. doi: 10.1038/s41416-020-01121-y. Epub 2020 Oct 22.
10
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.辅助纳武利尤单抗对比伊匹单抗用于可切除 IIIB-C 期和 IV 期黑色素瘤（CheckMate 238 研究）：一项多中心、双盲、随机、对照、III 期临床试验的 4 年结果。
Lancet Oncol. 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19.
Zotero 插件